Cloudbyz

MARCH 5, 2024

Biologics: Biologics are large, complex molecules, often proteins, that are produced using living cells. Mode of Action : Small Molecules: They often work by binding to specific sites on target proteins to inhibit or activate their function, which can affect various biological pathways inside the cell.

Development 97

Development Drugs Manufacturing Immune Response 97

The Pharma Data

DECEMBER 9, 2020

Vigil’s pipeline strategy is to target these diseases by combining a high-level understanding of microglia physiology, disease genotyping, and patient phenotyping to identify specific genetic variations associated with microglial dysfunction. It’s like taking out the trash.

Marketing 52

Marketing In-Vivo Protein In-Vitro 52

Delveinsight

JULY 30, 2020

The global Adrenoleukodystrophy market size for the forecast period 2020-30, which was estimated to be USD 922.43 The global Adrenoleukodystrophy market size for the forecast period 2020-30, which was estimated to be USD 922.43 Adrenoleukodystrophy Market Size. million in the 7MM in 2017.

Hormones 52

Hormones Marketing Gene Trials 52

Delveinsight

JANUARY 7, 2021

The startup recently raised USD 87 million to propel itself in a competitive market. It also slates to commence a Phase Ib trial of its second candidate, TERN-201, a vascular adhesion protein (VAP-1) inhibitor, with top-line data anticipated in the first half of 2022. Terns raises USD 87 Million for NASH drugs.

RNA 52

RNA Clinical Trials Clinical Trials Trials 52

Roots Analysis

JANUARY 28, 2024

By analyzing large datasets from various sources, such as clinical trials, genetic data, and EHRs, big data analytics can help identify new potential drug candidates, accelerate the drug discovery process, and lead to the development of more effective and targeted medicines.

Big Data 40

Big Data Medicine Marketing Clinical Trials 40

Roots Analysis

MAY 21, 2024

In fact, it has been observed that around 40% of the pharmaceutical drugs approved by regulatory organizations exhibit poor bioavailability / solubility. Further, every year, poor bioavailability is one of the main causes of drug failure in obtaining approval authorization.

Drug Delivery 40

Drug Delivery Drugs Gene Therapy Bioavailability 40

Delveinsight

SEPTEMBER 8, 2021

The exact cause of SLE is unknown; however, factors such as sunlight and drugs may precipitate the condition, and many studies have revealed a complex genetic basis. As per DelveInsight’s report on Benlysta (Belimumab) market forecast , the sale of Belimumab has kept on increasing year after year. Anifrolumab (MEDI-546).

Marketing 52

Marketing Sales FDA Approval Antibody 52